about
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.Antiretroviral Prophylaxis to Reduce Breast Milk Transmission of HIV Type 1: New Data but Still Questions.Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART eraRandomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trialAssociation of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.Antiretroviral therapy during pregnancy and the risk of an adverse outcome.Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.Antiretroviral treatment for children with peripartum nevirapine exposure.Antibody maturation and viral diversification in HIV-infected women.Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial.Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medicationInitiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants.Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi.Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant womenPharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPotential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants.Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medicationsAdvances in the prevention of vertical transmission of human immunodeficiency virus.Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant womenBaseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries.Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy.Infant outcomes after maternal antiretroviral exposure in resource-limited settings.A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothersStavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants.
P50
Q27690864-6BC6F69C-D644-4495-B58B-4DE6E013E03CQ30569674-4DDDDA6E-AEEE-46EC-BDA6-55F37C481E50Q31158739-CD2C0E64-F1C3-4B86-8E97-7108A0757371Q32068631-6DE93005-FA71-4B57-B454-1899F23A6DEAQ33362020-64A27AC3-9105-4DE2-BDE0-E40AA42C9277Q33572442-894D3466-1BC1-4B9D-9765-9CF8F5764BE6Q33657188-B96F762F-E677-4E61-A07D-BC7D1CC0D386Q33765130-0A37C4D4-9327-4708-9847-76BD864ECC63Q33788608-E0CFA2B3-5F74-42E3-B03A-D4E917C56515Q33873955-8F60C6DE-DBDD-445E-BAAA-1C8640AA24A5Q33959672-D8351186-CBED-4085-AFE5-EA0EEF019B5AQ34116017-A6751FCE-493A-4408-AB5D-CF487CB84851Q34181048-E9D6CBC2-A957-47ED-8144-C3FD34AD6F31Q34216455-8C86BCD6-8B00-4AE7-B6C2-CC49E2AFACA6Q34494986-3371BFA9-C022-43A6-B8C5-9E15B03FA317Q34608508-D4B90018-37A6-43C4-9289-FD3EF3C14ADAQ34634644-1C91CF30-8165-45FC-B6AD-3CDF4E23C852Q34657178-FE3DDB55-DFA6-45BF-9C82-454977DEAF7FQ34683397-F56358B5-73E5-4A81-A51A-58F7D7CA25CAQ34711999-21E3A140-BC34-4C1D-9DE7-370C63886010Q34745570-4970B356-95F3-4FDC-BC55-0169E1C5AE08Q34756810-4C5A2E78-0926-4874-B11A-AB4DB57AD211Q35074791-80816E1E-D751-4FBF-99BD-E6A92375B875Q35171059-7DEF0E06-2EFB-4366-82E7-D64AFBDD75C4Q35224956-0F7A6E46-EBDC-42DC-B58D-8D2C58849F77Q35452458-0D0CC8E8-7EB4-4348-AF2B-07DA58F388CFQ35547832-22560D08-41AD-4A00-87EB-76B7EA293DF1Q35598502-D18D372E-0056-4BE8-9125-D161A7AEF2A2Q35620778-6731C0BB-A81F-44A6-A9C3-E086F2E19302Q35622844-8E04FA6E-4701-441B-B38E-7DD12A9947A5Q35629692-09BD9E74-FD9E-48ED-BA72-5EFFD994D7B6Q35636071-A9A4F579-4F7B-4297-82A5-5382E15A075DQ35647376-F6855626-CC63-45E7-B120-E7C5CF191F04Q35682303-3CA4B1D3-0DFD-4005-B3F1-0014582889C0Q35840756-8E59E104-10D8-41DC-8252-693EAB067C99Q35917564-49ECB448-B782-4C3E-8CEE-36D961EAFC08Q35989706-5FE26A9D-AD22-4E75-A348-B891116A59E5Q35996783-86326457-5EA5-490E-A76F-D46B2A48CC45Q36077016-F4F962B1-CAC0-4FB6-B41E-D2DF4D526C44Q36113222-5175043E-2D5E-4A18-9848-F2A2545C4F92
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lynne Mofenson
@ast
Lynne Mofenson
@en
Lynne Mofenson
@es
Lynne Mofenson
@nl
Lynne Mofenson
@sl
type
label
Lynne Mofenson
@ast
Lynne Mofenson
@en
Lynne Mofenson
@es
Lynne Mofenson
@nl
Lynne Mofenson
@sl
prefLabel
Lynne Mofenson
@ast
Lynne Mofenson
@en
Lynne Mofenson
@es
Lynne Mofenson
@nl
Lynne Mofenson
@sl
P106
P1153
7006591993
P21
P31
P496
0000-0002-2818-9808